ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

calcipotriene

Also written as “LEO 90100”, “MC2-01 cream” and “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”.

Its studies are mostly in Psoriasis · Alopecia Areata, led by 10 companies.

Drug pageCalcipotriene: every studyMany companies study it; this page follows only the 37 they lead. All 70 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 15, 200537 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LEO Pharma220 open or runningphase 4since Sep 15, 2005Sep 15, 2005none ahead
MC2 Therapeuticsits history only50 open or runningphase 3since Oct 9, 2017Oct 9, 2017none ahead
Almirallits history only20 open or runningphase 3since Nov 11, 2015Nov 11, 2015none ahead
Mayne Pharma International Ptyits history only20 open or runningphase 1since Mar 15, 2012Mar 15, 2012none ahead
Abbottits history only10 open or runningphase 3since Dec 12, 2007Dec 12, 2007none ahead
Egymedicalpediaits history only10 open or runningno phasesince Jun 23, 2023Jun 23, 2023none ahead
GlaxoSmithKlineits history only10 open or runningphase 3since Jun 6, 2010Jun 6, 2010none ahead
Glenmark Pharmaceuticals Ltd. Indiaits history only10 open or runningphase 3since Nov 1, 2017Nov 1, 2017none ahead
Huadong Medicineits history only10 open or runningphase 3since Dec 11, 2025Dec 11, 2025none ahead
Tolmarits history only10 open or runningphase 1since Apr 6, 2017Apr 6, 2017none ahead

Also a collaborator on its studies: Bioskin.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of LEO Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Sep 15, 2005.

  1. Jan 17, 2006Phase 3 study in PsoriasisNCT00279162 · 160 enrolled · United States
  2. Mar 18, 2008Phase 3 study in Psoriasis VulgarisNCT00640822 · 782 enrolled · Canada, France, United Kingdom
  3. Apr 29, 2008Phase 3 study in Psoriasis VulgarisNCT00670241 · 458 enrolled · Canada
  4. Jun 3, 2008Phase 3 study in Psoriasis VulgarisNCT00691002 · 1,245 enrolled · Croatia, Germany, Poland and more
  5. Jun 23, 2008Phase 2 study in Psoriasis VulgarisNCT00704262 · 33 enrolled · United States, Canada, Germany and more
  6. Jan 5, 2009Phase 2 study in Psoriasis VulgarisNCT00817219 · 33 enrolled · United States
  7. Aug 25, 2010Phase 3 study in Psoriasis VulgarisNCT01188928 · 1,152 enrolled · United States
  8. Feb 16, 20122 phase 2 studies in Psoriasis VulgarisNCT01536938, NCT01536886
  9. May 8, 2012Phase 2 study in Psoriasis VulgarisNCT01600222 · 37 enrolled · Canada
  10. May 28, 2013Phase 3 study in Psoriasis VulgarisNCT01866163 · 426 enrolled · United States
  11. Aug 27, 2013Phase 1 study in Psoriasis VulgarisNCT01935869 · 224 enrolled · France
  12. Mar 12, 2015Phase 2 study in Psoriasis VulgarisNCT02387853 · 117 enrolled · United States, Netherlands, Poland and more
  13. Mar 29, 2019Phase 1 study in Psoriasis VulgarisNCT03898583 · 15 enrolled · Germany
  14. Jun 16, 2023Phase 3 study in Stable Plaque PsoriasisNCT05919082 · 604 enrolled · China

TargetBeta

VDR →read by rule
“Vitamin D receptor agonist”ChEMBL 37, by rule

Other programs on VDR

ProgramCompanyFurthest phaseStudies
Modified-release Calcifediol CapsuleruleOPKO Healthphase 310

Studies

All 22 LEO Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05919082Stable Plaque Psoriasis · China3CompletedFeb 23, 2024604
NCT03898583Psoriasis Vulgaris · Germany1CompletedOct 29, 201915
NCT02387853Psoriasis Vulgaris · United States, Netherlands, Poland and more2CompletedMar 28, 2018117
NCT01935869Psoriasis Vulgaris · France1CompletedNov 2013224
NCT01866163Psoriasis Vulgaris · United States3CompletedOct 2013426
NCT01600222Psoriasis Vulgaris · Canada2CompletedMay 201337
NCT01536938Psoriasis Vulgaris · United States2CompletedSep 2012303
NCT01536886Psoriasis Vulgaris · United States2CompletedSep 2012376
NCT01188928Psoriasis Vulgaris · United States3CompletedMar 20111,152
NCT00817219Psoriasis Vulgaris · United States2CompletedDec 201133
NCT00704262Psoriasis Vulgaris · United States, Canada, Germany and more2CompletedDec 200933
NCT00691002Psoriasis Vulgaris · Croatia, Germany, Poland and more3CompletedJan 20101,245
NCT00670241Psoriasis Vulgaris · Canada3CompletedFeb 2009458
NCT00640822Psoriasis Vulgaris · Canada, France, United Kingdom3CompletedJun 2009782
NCT00279162Psoriasis · United States3Completed160
NCT00263718Psoriasis Vulgaris · Canada, Germany, Ireland and more2Completed360
NCT00248456Psoriasis Vulgaris · China4Completed320
NCT00243464Psoriasis of Scalp · Belgium, Canada, Denmark and more3Completed300
NCT00216892Psoriasis Vulgaris · Belgium, Canada, France and more4Completed1,032
NCT00216879Psoriasis of Scalp · Canada, Denmark, France and more3Completed800
NCT00216840Psoriasis of Scalp · Belgium, Canada, Finland and more3Completed1,350
NCT00216827Psoriasis of Scalp · Canada, Denmark, France and more3Completed1,485

How it is read

Names in the registry

  • “LEO 90100”, 7 entries
  • “MC2-01 cream”, 4 entries
  • “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”, 3 entries
  • “Calcipotriol plus hydrocortisone (LEO 80190)”, 2 entries
  • “MC2-01 Cream”, 2 entries

Codes read as this program: P3073.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.